An Overview of Rifabutin (Mycobutin)
October 3, 2012
Other Names: Mycobutin, RFB
What is rifabutin?
Rifabutin is an antibacterial prescription medicine approved by the U.S. Food and Drug Administration (FDA) for the prevention of disseminated Mycobacterium avium complex (MAC) disease in people with advanced HIV infection. Disseminated MAC disease, also called disseminated MAC infection, is an opportunistic infection. An opportunistic infection is an infection that occurs more frequently or is more severe in people with weakened immune systems -- such as those infected with HIV -- than in people with healthy immune systems.
Rifabutin can also be used "off-label" to prevent and treat other opportunistic infections of HIV infection. "Off-label" use refers to use of an FDA-approved medicine in a manner different from that described on the medicine label. Good medical practice and the best interests of a patient sometimes require that a medicine be used "off-label."
What HIV-related opportunistic infections is rifabutin used for?
The Guidelines for Prevention and Treatment of Opportunistic Infections in HIV-Infected Adults and Adolescents, prepared by the U.S. Department of Health and Human Services (HHS) and the Centers for Disease Control and Prevention (CDC), includes recommendations on the HIV-related uses of rifabutin to:
What should I tell my health care provider before taking rifabutin?
Before taking rifabutin, tell your health care provider:
Ask your health care provider about possible side effects from rifabutin. Your health care provider will tell you what to do if you have side effects.
How should I take rifabutin?
Take rifabutin according to your health care provider's instructions. Your health care provider will tell you how much rifabutin to take and when to take it. Before you start rifabutin and each time you get a refill, read any printed information that comes with your medicine.
How should rifabutin be stored?
Where can I find more information about rifabutin?
More information about rifabutin is available:
This article was provided by AIDSinfo. Visit the AIDSinfo website to find out more about their activities and publications.